9EZI | pdb_00009ezi

Structure of single-domain antibody VHH_h5 in complex with human Vsig4


Experimental Data Snapshot

  • Method: X-RAY DIFFRACTION
  • Resolution: 1.97 Å
  • R-Value Free: 
    0.243 (Depositor), 0.242 (DCC) 
  • R-Value Work: 
    0.198 (Depositor), 0.198 (DCC) 
  • R-Value Observed: 
    0.200 (Depositor) 

Starting Model: experimental
View more details

wwPDB Validation   3D Report Full Report


This is version 1.1 of the entry. See complete history


Literature

In silico design of stable single-domain antibodies with high affinity.

Zhang, Z.van der Kant, R.Markovic, I.Vizarraga, D.Garcia, T.Maragkou, K.Delgado Blanco, J.Cianferoni, D.Orlando, G.Cia, G.Geukens, N.Carolis, C.Volkov, A.N.Savvides, S.N.Dewilde, M.Schymkowitz, J.Serrano Pubul, L.Rousseau, F.

(2026) Structure 

  • DOI: https://doi.org/10.1016/j.str.2025.12.010
  • Primary Citation of Related Structures:  
    9EZH, 9EZI, 9EZU, 9EZV, 9EZW

  • PubMed Abstract: 

    Designing antibodies is complex and resource intensive. While deep learning and generative approaches have shown promise in the design of protein binders, achieving high affinity and stability remains challenging. We introduce EvolveX, a structure-based antibody design pipeline leveraging the empirical force field FoldX to design complementarity-determining regions (CDRs) of single-domain antibodies (VHHs). We demonstrate the ability of EvolveX to redesign a VHH targeting mouse Vsig4 (mVsig4) to address two challenges: enhancing stability and affinity for mVsig4 and redesigning it for high affinity to the human ortholog. Notably, EvolveX improved the binding affinity of VHHs to human Vsig4 by over 1,000-fold. Structural analyses by X-ray crystallography confirmed design accuracy. Next-generation sequencing (NGS) analysis further demonstrated the efficiency of FoldX-based design pipeline. Collectively, our study highlights EvolveX's potential to overcome current limitations in antibody design, offering a powerful tool for the development of therapeutics with enhanced specificity, stability, and efficacy.


  • Organizational Affiliation
    • Switch Laboratory, VIB Center for Brain and Disease Research, VIB, 3000 Leuven, Belgium; Switch Laboratory, Department of Cellular and Molecular Medicine, KU Leuven, 3000 Leuven, Belgium; Switch Laboratory, VIB Center for AI & Computational Biology, VIB, 3000 Leuven, Belgium; Laboratory for Therapeutic and Diagnostic Antibodies, Department of Pharmaceutical and Pharmacological Sciences, KU Leuven, 3000 Leuven, Belgium.

Macromolecules
Find similar proteins by:  (by identity cutoff)  |  3D Structure
Entity ID: 1
MoleculeChains Sequence LengthOrganismDetailsImage
V-set and immunoglobulin domain-containing protein 4118Homo sapiensMutation(s): 0 
Gene Names: VSIG4CRIgZ39IGUNQ317/PRO362
UniProt & NIH Common Fund Data Resources
Find proteins for Q9Y279 (Homo sapiens)
Explore Q9Y279 
Go to UniProtKB:  Q9Y279
PHAROS:  Q9Y279
GTEx:  ENSG00000155659 
Entity Groups  
Sequence Clusters30% Identity50% Identity70% Identity90% Identity95% Identity100% Identity
UniProt GroupQ9Y279
Sequence Annotations
Expand
  • Reference Sequence
Find similar proteins by:  (by identity cutoff)  |  3D Structure
Entity ID: 2
MoleculeChains Sequence LengthOrganismDetailsImage
VHH_h5121CamelidaeMutation(s): 0 
Entity Groups  
Sequence Clusters30% Identity50% Identity70% Identity90% Identity95% Identity100% Identity
Sequence Annotations
Expand
  • Reference Sequence
Experimental Data & Validation

Experimental Data

  • Method: X-RAY DIFFRACTION
  • Resolution: 1.97 Å
  • R-Value Free:  0.243 (Depositor), 0.242 (DCC) 
  • R-Value Work:  0.198 (Depositor), 0.198 (DCC) 
  • R-Value Observed: 0.200 (Depositor) 
Space Group: P 21 21 21
Unit Cell:
Length ( Å )Angle ( ˚ )
a = 25.709α = 90
b = 50.877β = 90
c = 175.904γ = 90
Software Package:
Software NamePurpose
PHENIXrefinement
XDSdata reduction
Aimlessdata scaling
PHASERphasing

Structure Validation

View Full Validation Report



Entry History & Funding Information

Deposition Data


Funding OrganizationLocationGrant Number
Agencia Estatal de Investigacion (AEI)SpainJDC2022-048697-I

Revision History  (Full details and data files)

  • Version 1.0: 2025-10-29
    Type: Initial release
  • Version 1.1: 2026-01-21
    Changes: Database references